Mephobarbital

Summary

Mephobarbital (CHEMBL45029) is an approved small-molecule anticonvulsant (ATC N03AA01); indicated across 1 condition including epilepsy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N03AA01
• Indications: 1 condition
• Chemistry: 246.26 Da · C13H14N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL45029
Name	Mephobarbital
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	8271
ChEBI	CHEBI:6758
ATC	N03AA01
Molecular formula	C13H14N2O3
Molecular weight	246.26
InChIKey	ALARQZQTBTVLJV-UHFFFAOYSA-N

SMILES: CCC1(C(=O)NC(=O)N(C1=O)C)C2=CC=CC=C2

IUPAC name: 5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione

ChEBI definition: A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by ethyl and phenyl groups.

Pharmacological roles (ChEBI): anticonvulsant.

Also known as: Isonal, Mebaral, Menta-bal, Mephobarbital, Mephobarbital civ, Methylphenobarbital, Metilfenobarbital, Metylfenemal, Phemetone, Prominal, SID29215275, MEPHOBARBITAL

Patent coverage: 2,619 distinct patent families (11,110 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prelamin-A/C.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	6.35	Potency	446.7	nM	CHEMBL_ACT_3640040

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
epilepsy	4	MONDO:0005027	EFO:0000474

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).